{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:06:46Z","timestamp":1750910806406,"version":"3.41.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.soc.2024.12.005","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T04:14:51Z","timestamp":1737951291000},"page":"173-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic Advances and Novel Therapeutics in Peritoneal Metastasis"],"prefix":"10.1016","volume":"34","author":[{"given":"Gregory I.","family":"Sigler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Murtha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick R.","family":"Varley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib1","article-title":"Primary and metastatic peritoneal surface malignancies","volume":"7","author":"Cort\u00e9s-Guiral","year":"2021","journal-title":"Nat Rev Dis Prim"},{"first-page":"411, xii","year":"2016","author":"Ceelen","key":"10.1016\/j.soc.2024.12.005_bib2"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib3","doi-asserted-by":"crossref","DOI":"10.3348\/kjr.2023.0840","article-title":"Imaging evaluation of peritoneal metastasis: current and promising techniques","volume":"25","author":"Fu","year":"2024","journal-title":"Korean J Radiol"},{"issue":"6","key":"10.1016\/j.soc.2024.12.005_bib4","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1007\/s00330-019-06524-x","article-title":"Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis","volume":"30","author":"van 't Sant","year":"2020","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.soc.2024.12.005_bib5","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-008-0234-2","article-title":"Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis - PubMed","volume":"16","author":"Koh","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2024.12.005_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.crad.2012.07.015","article-title":"The role of CT and staging laparoscopy in the staging of gastric cancer","volume":"68","author":"Burbidge","year":"2013","journal-title":"Clin Radiol"},{"issue":"2","key":"10.1016\/j.soc.2024.12.005_bib7","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.2532082272","article-title":"Peritoneal metastasis: detection with 16- or 64-detector row CT in patients undergoing surgery for gastric cancer","volume":"253","author":"Kim","year":"2009","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib8","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.2016152601","article-title":"Abdominal imaging with contrast-enhanced photon-counting CT: first human experience","volume":"279","author":"Pourmorteza","year":"2016","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48641-z","article-title":"Hybrid Nano-GdF3 contrast media allows pre-clinical in\u00a0vivo element-specific K-edge imaging and quantification - PubMed","volume":"9","author":"Halttunen","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/s41747-018-0063-4","article-title":"Multicolour imaging with spectral photon-counting CT: a phantom study","volume":"2","author":"Si-Mohamed","year":"2018","journal-title":"Eur Radiol Exp"},{"issue":"10","key":"10.1016\/j.soc.2024.12.005_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/RLI.0000000000000483","article-title":"Improved peritoneal cavity and abdominal organ imaging using a biphasic contrast agent protocol and spectral photon counting computed tomography K-edge imaging","volume":"53","author":"Si-Mohamed","year":"2018","journal-title":"Invest Radiol"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70282-w","article-title":"Spectral photon-counting CT imaging of colorectal peritoneal metastases: initial experience in rats","volume":"10","author":"Thivolet","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.soc.2024.12.005_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.916693","article-title":"Frontiers | ImmunoPET: antibody-based PET imaging in solid tumors","volume":"9","author":"Manafi-Farid","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.soc.2024.12.005_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1026083","article-title":"Frontiers | Immuno-PET: design options and clinical proof-of-concept","volume":"9","author":"Lugat","year":"2022","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1358\/dot.2014.50.1.2076506","article-title":"The unexpected side effects and safety of therapeutic monoclonal antibodies","volume":"50","author":"Liu","year":"2014","journal-title":"Drugs Today (Barc)"},{"issue":"5","key":"10.1016\/j.soc.2024.12.005_bib16","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s11307-016-1041-y","article-title":"Molecular simulation of receptor occupancy and tumor penetration of an antibody and smaller scaffolds: application to molecular imaging","volume":"19","author":"Orcutt","year":"2017","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"10.1016\/j.soc.2024.12.005_bib17","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00259-020-04989-3","article-title":"Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study","volume":"48","author":"Touchefeu","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.soc.2024.12.005_bib18","doi-asserted-by":"crossref","first-page":"e220749","DOI":"10.1148\/radiol.220749","article-title":"Fapi PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease","volume":"306","author":"Mori","year":"2023","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.soc.2024.12.005_bib19","article-title":"The role of fibroblast activation protein in health and malignancy - PubMed","volume":"39","author":"AA","year":"2020","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib20","article-title":"Comparison of 68GA-FAPI-04 PET\/CT and 18F-FDG PET\/CT findings in peritonitis carcinomatosa cases - PubMed","volume":"26","author":"Y","year":"2023","journal-title":"Hellenic J Nucl Med"},{"issue":"6","key":"10.1016\/j.soc.2024.12.005_bib21","article-title":"Role of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET\/CT - PubMed","volume":"48","author":"L","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.soc.2024.12.005_bib22","article-title":"Evaluation of 68Ga-FAPI PET\/CT and 18F-FDG PET\/CT for the diagnosis of recurrent colorectal cancers","volume":"49","author":"Xi","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib23","article-title":"Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in patients presenting with inconclusive [18F]FDG PET\/CT findings - PubMed","volume":"48","author":"H","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"4","key":"10.1016\/j.soc.2024.12.005_bib24","doi-asserted-by":"crossref","DOI":"10.1007\/s00330-022-09251-y","article-title":"Usefulness of [68Ga]FAPI-04 and [18F]FDG PET\/CT for the detection of primary tumour and metastatic lesions in gastrointestinal carcinoma: a comparative study - PubMed","volume":"33","author":"Li","year":"2023","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.crad.2019.09.122","article-title":"Artificial intelligence in clinical imaging: a health system approach","volume":"75","author":"Gilbert","year":"2020","journal-title":"Clin Radiol"},{"issue":"2","key":"10.1016\/j.soc.2024.12.005_bib26","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.soc.2024.12.005_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.artmed.2018.09.003","article-title":"Towards a modular decision support system for radiomics: a case study on rectal cancer","volume":"96","author":"Gatta","year":"2019","journal-title":"Artif Intell Med"},{"issue":"12","key":"10.1016\/j.soc.2024.12.005_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.soc.2024.12.005_bib29","article-title":"Radiomics analysis using contrast-enhanced CT for preoperative prediction of occult peritoneal metastasis in advanced gastric cancer","volume":"30","author":"Liu","year":"2019","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.soc.2024.12.005_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz001","article-title":"Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer","volume":"30","author":"Dong","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2024.12.005_bib31","doi-asserted-by":"crossref","first-page":"109326","DOI":"10.1016\/j.ejrad.2020.109326","article-title":"Preoperative prediction of peritoneal metastasis in colorectal cancer using a clinical-radiomics model","volume":"132","author":"Li","year":"2020","journal-title":"Eur J Radiol"},{"issue":"7","key":"10.1016\/j.soc.2024.12.005_bib32","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.acra.2022.09.001","article-title":"A\u00a0CT-based radiomics model for evaluating peritoneal cancer index in peritoneal metastasis cases: a preliminary study","volume":"30","author":"Zhang","year":"2023","journal-title":"Acad Radiol"},{"issue":"6","key":"10.1016\/j.soc.2024.12.005_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10585-023-10235-5","article-title":"CT-based deep learning model: a novel approach to the preoperative staging in patients with peritoneal metastasis","volume":"40","author":"Wang","year":"2023","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.soc.2024.12.005_bib34","first-page":"1716268","article-title":"A\u00a0nomogram combining MRI multisequence radiomics and clinical factors for predicting recurrence of high-grade serous ovarian carcinoma","volume":"2022","author":"Li","year":"2022","journal-title":"J\u00a0Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/j.soc.2024.12.005_bib36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/20014091084218","article-title":"Clinical uses of tumor markers: a critical review","volume":"38","author":"Duffy","year":"2001","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"5","key":"10.1016\/j.soc.2024.12.005_bib37","article-title":"Use of tumor markers in gastrointestinal cancers: surgeon perceptions and cost-benefit trade-off analysis - PubMed","volume":"24","author":"A","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2024.12.005_bib38","article-title":"Predictive and prognostic biomarkers in colorectal cancer: a systematic review of recent advances and challenges - PubMed","volume":"87","author":"Vishal","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.soc.2024.12.005_bib39","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00572","article-title":"Highly sensitive circulating tumor DNA assay aids clinical management of radiographically occult isolated peritoneal metastases in patients with GI cancer","volume":"6","author":"Singh","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.soc.2024.12.005_bib40","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1245\/s10434-018-6561-z","article-title":"Preoperative circulating tumor DNA in patients with peritoneal carcinomatosis is an independent predictor of progression-free survival","volume":"25","author":"Baumgartner","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.soc.2024.12.005_bib41","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1245\/s10434-020-08331-x","article-title":"Prognostic utility of pre- and postoperative circulating tumor DNA liquid biopsies in patients with peritoneal metastases","volume":"27","author":"Baumgartner","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2024.12.005_bib42","article-title":"Circulating tumor DNA as a preoperative marker of recurrence in patients with peritoneal metastases of colorectal cancer: a clinical feasibility study","volume":"9","author":"Beagan","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.soc.2024.12.005_bib43","doi-asserted-by":"crossref","first-page":"e2100535","DOI":"10.1200\/PO.21.00535","article-title":"Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer","volume":"6","author":"Bando","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.soc.2024.12.005_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdn176","article-title":"Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004 - PubMed","volume":"19","author":"Meulenbeld","year":"2008","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.soc.2024.12.005_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2012.03.008","article-title":"Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy","volume":"38","author":"Klaver","year":"2012","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"10.1016\/j.soc.2024.12.005_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdq762","article-title":"Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy","volume":"22","author":"Klaver","year":"2011","journal-title":"Ann Oncol"},{"issue":"3\u20134","key":"10.1016\/j.soc.2024.12.005_bib47","article-title":"Metastatic colorectal cancer: from improved survival to potential cure","volume":"78","author":"Gallaghar","year":"2010","journal-title":"Oncology"},{"issue":"9","key":"10.1016\/j.soc.2024.12.005_bib48","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.soc.2024.12.005_bib49","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.soc.2024.12.005_bib50","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.soc.2024.12.005_bib51","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.soc.2024.12.005_bib52","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/annonc\/mdn403","article-title":"Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie","volume":"19","author":"Al-Batran","year":"2008","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.soc.2024.12.005_bib53","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ijc.29403","article-title":"NeoFLOT: multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors","volume":"137","author":"Schulz","year":"2015","journal-title":"Int J Cancer"},{"issue":"10184","key":"10.1016\/j.soc.2024.12.005_bib54","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.soc.2024.12.005_bib55","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2024.12.005_bib56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","article-title":"Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent","volume":"64","author":"Carteni","year":"2009","journal-title":"Lung Cancer"},{"issue":"23","key":"10.1016\/j.soc.2024.12.005_bib57","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"30","key":"10.1016\/j.soc.2024.12.005_bib58","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2024.12.005_bib59","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.soc.2024.12.005_bib60","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ijc.32606","article-title":"Final results from GCIG\/ENGOT\/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer","volume":"146","author":"Ray-Coquard","year":"2020","journal-title":"Int J Cancer"},{"issue":"20","key":"10.1016\/j.soc.2024.12.005_bib61","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2024.12.005_bib62","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.2147\/CMAR.S186042","article-title":"The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer","volume":"11","author":"Battaglin","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"34","key":"10.1016\/j.soc.2024.12.005_bib63","doi-asserted-by":"crossref","first-page":"e29992","DOI":"10.1097\/MD.0000000000029992","article-title":"Trastuzumab combined chemotherapy for the treatment of HER2-positive advanced gastric cancer: a systematic review and meta-analysis of randomized controlled trial","volume":"101","author":"Xue","year":"2022","journal-title":"Medicine (Baltim)"},{"issue":"5","key":"10.1016\/j.soc.2024.12.005_bib64","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1053\/j.gastro.2015.06.047","article-title":"Genetics and genetic biomarkers in sporadic colorectal cancer","volume":"149","author":"Carethers","year":"2015","journal-title":"Gastroenterology"},{"issue":"23","key":"10.1016\/j.soc.2024.12.005_bib65","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.soc.2024.12.005_bib66","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.soc.2024.12.005_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cells12020258","article-title":"Immunotherapy: recent advances and its future as a neoadjuvant, adjuvant, and primary treatment in colorectal cancer","volume":"12","author":"Yu","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.soc.2024.12.005_bib68","doi-asserted-by":"crossref","first-page":"102665","DOI":"10.1016\/j.ctrv.2023.102665","article-title":"Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: current strategies and future challenges","volume":"122","author":"Ying","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"23","key":"10.1016\/j.soc.2024.12.005_bib69","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.soc.2024.12.005_bib70","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.21037\/atm-22-6196","article-title":"Advances in adoptive cellular therapy for colorectal cancer: a narrative review","volume":"10","author":"Yi","year":"2022","journal-title":"Ann Transl Med"},{"issue":"21","key":"10.1016\/j.soc.2024.12.005_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111781","article-title":"Cell therapy for colorectal cancer: the promise of chimeric antigen receptor (CAR)-T cells","volume":"22","author":"Aparicio","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.soc.2024.12.005_bib72","doi-asserted-by":"crossref","first-page":"841425","DOI":"10.3389\/fimmu.2022.841425","article-title":"Update for advance CAR-T therapy in solid tumors, clinical application in peritoneal carcinomatosis from colorectal cancer and future prospects","volume":"13","author":"Qian","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.soc.2024.12.005_bib73","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/cncr.29134","article-title":"The rise in metastasectomy across cancer types over the past decade","volume":"121","author":"Bartlett","year":"2015","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.soc.2024.12.005_bib74","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s004230050246","article-title":"Management of peritoneal-surface malignancy: the surgeon's role","volume":"384","author":"Sugarbaker","year":"1999","journal-title":"Langenbeck's Arch Surg"},{"first-page":"184","year":"2021","series-title":"Updates in surgery","key":"10.1016\/j.soc.2024.12.005_bib75"},{"issue":"5","key":"10.1016\/j.soc.2024.12.005_bib76","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/SLA.0000000000004326","article-title":"Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year national French practice","volume":"272","author":"Noiret","year":"2020","journal-title":"Ann Surg"},{"issue":"13","key":"10.1016\/j.soc.2024.12.005_bib77","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/bjs.9674","article-title":"Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei","volume":"101","author":"Kusamura","year":"2014","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.soc.2024.12.005_bib78","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/SLA.0b013e3182436c28","article-title":"Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies","volume":"255","author":"Kusamura","year":"2012","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.soc.2024.12.005_bib79","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1245\/s10434-014-4111-x","article-title":"Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies","volume":"22","author":"Polanco","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.soc.2024.12.005_bib80","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/bjs.5863","article-title":"Learning curve of combined modality treatment in peritoneal surface disease","volume":"94","author":"Smeenk","year":"2007","journal-title":"Br J Surg"},{"key":"10.1016\/j.soc.2024.12.005_bib81","series-title":"Textbook of Complex general surgical oncology","article-title":"American board of surgery certificate in Complex general surgical oncology: rationale and history","author":"Golas","year":"2018"},{"issue":"28","key":"10.1016\/j.soc.2024.12.005_bib82","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1200\/JCO.2008.20.1715","article-title":"Centralization of cancer surgery: implications for patient access to optimal care","volume":"27","author":"Stitzenberg","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.soc.2024.12.005_bib83","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/bja\/78.5.606","article-title":"Multimodal approach to control postoperative pathophysiology and rehabilitation","volume":"78","author":"Kehlet","year":"1997","journal-title":"Br J Anaesth"},{"issue":"12","key":"10.1016\/j.soc.2024.12.005_bib84","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ejso.2020.07.041","article-title":"Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS\u00ae) society Recommendations \u2014 Part I: preoperative and intraoperative management","volume":"46","author":"H\u00fcbner","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"10.1016\/j.soc.2024.12.005_bib85","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.ejso.2020.08.006","volume":"46","author":"H\u00fcbner","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib86","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1245\/s10434-019-07900-z","article-title":"Implementation of an enhanced recovery after surgery (ERAS) program is associated with improved outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"27","author":"Webb","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.soc.2024.12.005_bib87","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1245\/s10434-020-09476-5","article-title":"Impact of enhanced recovery after surgery on postoperative outcomes for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"28","author":"White","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2024.12.005_bib88","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1245\/s10434-024-15120-3","article-title":"Improved postoperative pain management outcomes after implementation of enhanced recovery after surgery (ERAS) protocol for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)","volume":"31","author":"Yue","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"10.1016\/j.soc.2024.12.005_bib89","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study","volume":"22","author":"Glehen","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2024.12.005_bib90","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1245\/s10434-009-0487-4","article-title":"A\u00a0systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin","volume":"16","author":"Cao","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.soc.2024.12.005_bib91","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1245\/s10434-018-6631-2","article-title":"Impact of combination chemotherapy in peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy (HIPEC): the RENAPE study","volume":"25","author":"Malgras","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.soc.2024.12.005_bib92","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10434-999-0727-7","article-title":"Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy","volume":"6","author":"Sugarbaker","year":"1999","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"10.1016\/j.soc.2024.12.005_bib93","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2024.12.005_bib94","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.soc.2024.12.005_bib95","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.soc.2024.12.005_bib96","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","article-title":"Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial","volume":"30","author":"Koole","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.soc.2024.12.005_bib97","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1200\/JCO.22.02867","article-title":"Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial","volume":"42","author":"Rau","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.soc.2024.12.005_bib98","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","article-title":"Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer: a phase 3 randomized clinical trial","volume":"158","author":"Arjona-Sanchez","year":"2023","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.soc.2024.12.005_bib99","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Quenet","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.soc.2024.12.005_bib100","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","article-title":"Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study","volume":"21","author":"Goere","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.soc.2024.12.005_bib101","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.soc.2024.12.005_bib102","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s00432-016-2234-0","article-title":"Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model","volume":"142","author":"Khosrawipour","year":"2016","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib103","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s004649900010","article-title":"Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator","volume":"14","author":"Reymond","year":"2000","journal-title":"Surg Endosc"},{"issue":"4","key":"10.1016\/j.soc.2024.12.005_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041125","article-title":"10 Years of pressurized intraperitoneal aerosol chemotherapy (PIPAC): a systematic review and meta-analysis","volume":"15","author":"Di Giorgio","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.soc.2024.12.005_bib105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1515\/pp-2022-0111","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne","volume":"7","author":"Casella","year":"2022","journal-title":"Pleura Peritoneum"},{"issue":"3","key":"10.1016\/j.soc.2024.12.005_bib106","doi-asserted-by":"crossref","DOI":"10.1515\/pp-2018-0114","volume":"3","author":"Bakrin","year":"2018","journal-title":"Pleura and Peritoneum"},{"key":"10.1016\/j.soc.2024.12.005_bib116","first-page":"928","article-title":"Sur le culture de virus vaccinal dans les neoplasmes epithelieux","volume":"86","author":"Levaditi","year":"1922","journal-title":"CR Soc Biol"},{"issue":"9","key":"10.1016\/j.soc.2024.12.005_bib107","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.soc.2024.12.005_bib108","first-page":"1562","article-title":"Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3\u00a0weeks in patients with recurrent\/refractory epithelial ovarian cancer","volume":"20","author":"Vasey","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2024.12.005_bib109","series-title":"Cancer regional therapy: HAI, HIPEC, HILP, ILI, PIPAC and beyond","first-page":"221","article-title":"Novel techniques and the future of HIPEC (immunotherapy, viral therapy)","author":"Beane","year":"2020"},{"issue":"13","key":"10.1016\/j.soc.2024.12.005_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28135145","article-title":"Cancer nanomedicine: emerging strategies and therapeutic potentials","volume":"28","author":"Xu","year":"2023","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.soc.2024.12.005_bib111","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.2008.18.9548","article-title":"Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer","volume":"27","author":"Teneriello","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib112","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ygyno.2011.03.036","article-title":"A\u00a0phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"122","author":"Coleman","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.12.005_bib113","doi-asserted-by":"crossref","first-page":"e067691","DOI":"10.1136\/bmjopen-2022-067691","article-title":"Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity","volume":"13","author":"Lang","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.soc.2024.12.005_bib114","doi-asserted-by":"crossref","first-page":"104151","DOI":"10.1016\/j.ebiom.2022.104151","article-title":"Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases","volume":"82","author":"Ceelen","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.soc.2024.12.005_bib115","doi-asserted-by":"crossref","first-page":"1070362","DOI":"10.3389\/fmed.2023.1070362","article-title":"First experience with (224)Radium-labeled microparticles (Radspherin(R)) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study)","volume":"10","author":"Larsen","year":"2023","journal-title":"Front Med (Lausanne)"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320724000917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320724000917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T14:46:45Z","timestamp":1750862805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320724000917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1055320724000917"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2024.12.005","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic Advances and Novel Therapeutics in Peritoneal Metastasis","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}